# How Brain Tumors and Thyroid Cancer Brain Metastases with the BRAF V600E Mutation Escape Cell Death

This review examines two BRAF V600E-driven cancer settings. The first setting is selected primary brain tumors: pleomorphic xanthoastrocytoma and ganglioglioma. The second setting is thyroid cancer that has spread to the brain. The review examines how these settings evade programmed cell death. The authors separate direct evidence from indirect and hypothesis-generating evidence, and they stress that a shared BRAF V600E mutation does not make these diseases biologically equivalent. Clinical trials support BRAF/MEK inhibition in BRAF V600E-mutant glioma and systemic anaplastic thyroid cancer. However, direct evidence inside the brain for thyroid cancer brain metastases remains very limited and confounded. The blood–brain barrier, the heterogeneous blood–tumor barrier, drug efflux transporters, and the brain microenvironment all complicate any inference from systemic treatment results.

# How Brain Tumors and Thyroid Cancer Brain Metastases with the BRAF V600E Mutation Escape Cell Death

## Table of Contents

- Key Points
- Background: Why This Research Matters
- How the Researchers Reviewed the Evidence
- Molecular Landscape: How Common Is BRAF V600E in These Tumors?
- Evading Cell Death Through Apoptosis Mechanisms
- Evading Cell Death Through Ferroptosis Mechanisms
- CNS-Specific Barriers to Treatment Activity
- Clinical Evidence for BRAF/MEK-Targeted Therapy
- Clinical Implications for Patients
- Limitations: What This Review Could Not Establish
- Recommendations and Research Priorities
- Frequently Asked Questions
- Source Information

## Key Points

- A shared BRAF V600E mutation does not make different cancers biologically equivalent; molecular eligibility must be confirmed within each specific tumor type.
- Clinical trials support BRAF/MEK inhibition in BRAF V600E-mutant glioma and systemic anaplastic thyroid cancer, but not as proof of intracranial benefit.
- Direct evidence inside the brain for thyroid cancer brain metastases remains very limited and confounded by prior treatments and few baseline cases.
- The blood–brain barrier, heterogeneous blood–tumor barrier, efflux transporters, and brain microenvironment complicate inference from systemic treatment results.
- A radiographic response to BRAF/MEK inhibition should be described as clinical activity, not proof that a particular apoptotic node was restored.

## Background: Why This Research Matters

Primary tumors of the central nervous system (CNS, meaning the brain and spinal cord) differ in their cell of origin. Brain metastases (cancer that started elsewhere and spread to the brain) also differ in their cell of origin. These tumors also differ in their tissue appearance under the microscope, their natural course, and their treatment context. This review focuses on selected tumors in which the BRAF V600E mutation is clinically or biologically relevant.

The BRAF V600E mutation means that the amino acid valine is replaced by glutamic acid at position 600 of the BRAF protein. This change keeps the mitogen-activated protein kinase (MAPK) signaling pathway switched on continuously. That constant signaling gives a rationale for using BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) as treatment.

However, the authors emphasize a key point: a shared driver mutation is not a shared disease identity. The relative importance of several factors differs across the tumor types included in this review. These factors are apoptosis (programmed cell death), ferroptosis (an iron-dependent form of cell death), lineage-specific co-alterations, immune context, and drug exposure inside the CNS.

The review uses this comparison as a structured framework. It asks which mechanisms are established in a stated disease context, which are indirect, and which remain untested. The authors explicitly state that the review is not used to infer that a mechanism is established in pleomorphic xanthoastrocytoma, ganglioglioma, or thyroid cancer brain metastases (TCBM). This applies to a mechanism demonstrated in melanoma, colorectal cancer, extracranial thyroid cancer, or another brain-metastasis model.

The clinical importance of TCBM is supported by a 27-patient cohort. In that cohort, median survival after diagnosis of CNS metastasis was 5.0 months. However, the histologies and treatments in that cohort were heterogeneous, and outcomes were not stratified by BRAF status.

The review considers programmed cell death through two tractable axes: mitochondrial apoptosis and ferroptosis. Their relevance is linked to the clinical activity of MAPK inhibition. Yet a clinical response alone cannot identify which death pathway is engaged in a patient's lesion. The review therefore keeps mechanistic studies separate from treatment-outcome studies. It treats the blood–brain barrier (BBB), the blood–tumor barrier (BTB), and the brain microenvironment as modifiers rather than deterministic explanations for resistance.

## How the Researchers Reviewed the Evidence

The literature search included publications available through July 29, 2026. The authors examined PubMed and PubMed Central records, Crossref metadata, journal and DOI pages, and primary trial publications. They used combinations of search terms for BRAF V600E, PXA, ganglioglioma, epithelioid glioblastoma, pilocytic astrocytoma, and pediatric low-grade glioma (pLGG). They also used search terms for thyroid cancer, TCBM, apoptosis, BIM, BCL-xL, MCL-1, ferroptosis, SLC7A11, GPX4, FSP1, and DHODH. They also used search terms for BBB, BTB, ABCB1, ABCG2, astrocytes, and immunotherapy. Searches also targeted named trials and regimens when numerical clinical outcomes required verification.

The authors prioritized primary peer-reviewed experimental studies and original clinical-trial reports. They used reviews for orientation or cross-checking, but not as substitutes for primary support for clinical outcomes. Search-result snippets, news reports, company pages, and secondary medical websites were not used to confirm response rates, survival, frequencies, or pharmacokinetic parameters. Preprints were checked for a formally published version, and the peer-reviewed publication was used when available. The republished 2023 TRICOTEL report was used instead of the retracted 2022 version.

The authors classified evidence into several categories:

- Direct clinical or preclinical evidence in the stated target CNS context
- Evidence in the same tumor type outside the CNS
- Indirect evidence from another brain-tumor or brain-metastasis context
- Evidence from another BRAF-mutant cancer
- General pathway biology
- Hypothesis-generating extrapolation

Numerical data were retained only when traceable to an audited primary source. Unavailable outcomes are reported as "not reported" (NR). The authors note that this was a narrative review. It did not use a PRISMA workflow, protocol registration, dual independent screening, formal risk-of-bias assessment, or meta-analysis.

## Molecular Landscape: How Common Is BRAF V600E in These Tumors?

The frequency of BRAF V600E depends heavily on histology (tissue type), referral population, assay method, anatomic site, and the classification era in which tumors were diagnosed. The authors stress that these estimates should not be treated as universal prevalence estimates, because cohort selection and contemporary classification affect the denominator.

In a direct-sequencing series, the mutation was detected in 42 of 64 grade 2 pleomorphic xanthoastrocytoma (PXA) tumors (66%) and in 15 of 23 tumors then classified as anaplastic PXA (65%). A second selected PXA cohort, using VE1 immunohistochemistry with sequencing, identified BRAF V600E in 38 of 49 tumors (78%).

In the same historical direct-sequencing study, BRAF V600E occurred in 14 of 77 grade 1 gangliogliomas (18%) and in 3 of 6 anaplastic gangliogliomas. The authors note that the six-case denominator and the historical category limit interpretation.

The mutation is less uniformly distributed in pilocytic astrocytoma. Schindler and colleagues detected it in 9 of 97 tumors (9%), including 4 of 12 diencephalic tumors. This finding emphasizes site dependence and the need to distinguish BRAF V600E from BRAF fusions.

In a pediatric low-grade glioma cohort, 69 of 405 evaluable tumors (17%) carried BRAF V600E. However, proportions varied markedly by histology:

- 5 of 167 pilocytic astrocytomas
- 25 of 51 gangliogliomas
- 7 of 9 PXA tumors

A small historical epithelioid glioblastoma series identified the mutation in 7 of 13 tumors (54%) by mutational analysis. The authors note that this estimate is classification-sensitive, because some historical tumors may be reassigned under contemporary integrated diagnosis.

Thyroid-cancer estimates require the same contextual discipline. Lan and colleagues analyzed a selected 66-patient papillary thyroid carcinoma (PTC) cohort. That cohort comprised 20 patients with distant metastasis and 46 patients without distant metastasis. BRAF V600E was identified in 48 of 66 tumors (72.7%) overall. The authors stress that this cohort-wide estimate is neither a prevalence estimate for metastatic PTC nor a general prevalence estimate for classical PTC.

A separate single-institution cohort reported the alteration in 162 of 185 classical PTCs (88%), with strong dependence on subtype and testing context. The authors warn that these values must not be combined into a universal frequency range.

In recurrent PTC, coexisting BRAF V600E and TERT-promoter mutations were strongly associated with loss of radioiodine avidity. The authors note that this association does not establish deterministic progression to anaplastic thyroid carcinoma (ATC) or brain metastasis.

Available TCBM cohorts do not provide a reliable BRAF-stratified frequency or a uniform molecular profile. The authors therefore present cohort-bound estimates and retain "not reported" where an audited primary source did not report a required item.

This distribution has two implications for the comparison. First, molecular eligibility must be confirmed within each histologic entity rather than inferred from a broad diagnostic label. Second, frequency is not a measure of pathway dependence, cell-death phenotype, or treatment benefit.

A high proportion in a selected PXA or classical PTC cohort does not show that the two diseases share co-alterations or a response mechanism. Conversely, a lower frequency in ganglioglioma or pilocytic astrocytoma does not reduce the potential relevance of a confirmed mutation for an individual patient. These distinctions are especially important for TCBM, where the brain-metastasis cohort evidence is sparse and does not permit reconstruction of a BRAF V600E prevalence estimate from extracranial PTC cohorts.

## Evading Cell Death Through Apoptosis Mechanisms

MAPK activation can alter the threshold for cell death, but the evidence is uneven across the reviewed tumors. The authors state that mechanistic components should be interpreted at the level of the experimental model in which they were demonstrated. An integrated BRAF–apoptosis–ferroptosis network has not been directly established in TCBM. Genotype-defined ferroptosis studies in the selected primary CNS tumors remain lacking.

Mitochondrial apoptosis is governed by the balance between BH3-only proteins, anti-apoptotic BCL-2 family members, and the BAX/BAK effectors. These effectors enable mitochondrial outer-membrane permeabilization (MOMP).

In BRAF V600E melanoma models, ERK-dependent signaling reduced the pro-apoptotic protein BIM through phosphorylation-linked turnover. Melanoma studies also implicated MCL-1 upregulation in resistance to BRAFi alone or with MEKi. Combined analyses of MCL-1 and BCL-xL showed how anti-apoptotic buffering can constrain BAX/BAK-dependent death during MAPK inhibition. The authors note that these experiments provide an indirect mechanistic framework. They do not demonstrate the same dependency in PXA, ganglioglioma, or TCBM.

More disease-proximal evidence comes from non-CNS thyroid-cancer models. In PTC and ATC cell systems, BRAF V600E-associated mitochondrial phospho-ERK/phospho-GSK-3β signaling was linked to cyclophilin D (CypD) regulation. This signaling was also linked to inhibition of mitochondrial permeability transition pore (mPTP) opening and to reduced staurosporine-induced cell death. The authors state that this supports a thyroid cancer-specific mitochondrial mechanism outside the brain. It is not a mechanism demonstrated in TCBM patient samples. It also should not be combined with melanoma BIM or MCL-1 findings to imply that a single complete apoptotic circuit has been proven across all BRAF V600E tumors.

For selected primary CNS tumors, clinical sensitivity to BRAFi/MEKi establishes MAPK dependence in some lesions. However, it does not establish which apoptotic nodes mediate response. Direct studies are needed. These studies should test BIM degradation, BCL-xL/MCL-1 stabilization, BAX/BAK activation, MOMP, and the mitochondrial ERK/GSK-3β/CypD/mPTP axis in molecularly defined PXA, ganglioglioma, and TCBM.

Until then, these nodes may contribute to resistance and provide experimentally testable hypotheses. Disease-specific causality remains to be validated. A useful experimental sequence would test pathway suppression, BIM abundance, anti-apoptotic buffering, BAX/BAK activation, and mitochondrial permeabilization within the same genotype-defined model. Rescue experiments would be needed to distinguish association from dependence.

For TCBM, paired extracranial and intracranial material would also be required to determine whether the brain site changes the apoptotic threshold. Without such linked measurements, a radiographic response to BRAFi/MEKi should be described as clinical activity rather than proof that a particular apoptotic node was restored.

## Evading Cell Death Through Ferroptosis Mechanisms

Ferroptosis is driven by iron-dependent lipid peroxidation and opposed by several redox-defense systems. The system Xc– transporter, which includes SLC7A11, supports cystine uptake and glutathione (GSH) synthesis. Glutathione peroxidase 4 (GPX4) reduces phospholipid hydroperoxides.

Ferroptosis suppressor protein 1 (FSP1) can regenerate reduced coenzyme Q10 (CoQ10) at membranes independently of GPX4. Mitochondrial dihydroorotate dehydrogenase (DHODH) provides a complementary defense in general cancer models. The authors state that FSP1/CoQ10 and DHODH are established general mechanisms, not validated dependencies in TCBM or the selected BRAF V600E primary CNS tumors.

The most relevant genotype-defined evidence is preclinical and extracranial. Ferroptosis sensitization has been demonstrated preclinically in BRAF V600E anaplastic thyroid cancer outside the brain. The FSP1/CoQ10 axis and DHODH remain general mechanistic frameworks rather than established dependencies in the target CNS settings.

The authors state that the priority is not to assume a universal ferroptosis-resistant state. Instead, the priority is to measure lipid-peroxidation sensitivity, iron handling, SLC7A11/GPX4 dependence, FSP1/CoQ10 activity, and DHODH dependence. These measurements should be made in molecularly characterized PXA, ganglioglioma, and paired thyroid primary/brain metastasis models.

Such studies should test whether MAPK inhibition changes ferroptosis sensitivity in a compound- and context-dependent manner. They should also include CNS exposure and toxicity constraints. Interpretation should remain intervention-specific. Sensitivity to one GPX4 inhibitor cannot be used to predict sensitivity to system Xc– inhibition. A genotype-associated difference for erastin does not establish synergy with dabrafenib. Likewise, an increased labile iron pool may create vulnerability, but it is not itself evidence that ferroptosis occurs in a treated patient.

Minimum target-context studies should combine genetic and pharmacologic perturbation, verify lipid peroxidation-dependent death, and demonstrate rescue by a ferroptosis-specific intervention. In brain models, these endpoints should be interpreted alongside neuronal and glial toxicity and the unbound exposure achieved at the lesion.

## CNS-Specific Barriers to Treatment Activity

The intact blood–brain barrier (BBB) and the tumor-associated blood–tumor barrier (BTB) are related but not interchangeable. The BBB is formed by specialized endothelial junctions and transport systems that regulate access to normal brain. Primary CNS tumors and brain metastases can disrupt this architecture, but disruption is spatially heterogeneous.

In experimental brain metastases, permeability varied among and within lesions. Drug uptake could remain lower than in peripheral tissue despite contrast enhancement on imaging. The authors also describe preclinical ABCB1/ABCG2 efflux, meaning these transporter proteins pump drugs out of cells. They label reactive-astrocyte/IL-23 and stromal HGF/MET bypass evidence as indirect brain-metastasis evidence.

The authors state that the intact BBB, the heterogeneous BTB, efflux transporters, and the brain microenvironment further complicate inference from systemic outcomes. They treat these barriers as modifiers rather than deterministic explanations for resistance.

## Clinical Evidence for BRAF/MEK-Targeted Therapy

Clinical studies support BRAF/MEK inhibition in BRAF V600E-mutant glioma and systemic anaplastic thyroid cancer. However, direct TCBM intracranial evidence is restricted to very limited, confounded observations. The authors separate direct, indirect, and hypothesis-generating evidence.

In the ROAR basket trial, adults with BRAF V600E glioma received dabrafenib plus trametinib. The objective response rate (ORR) was 54% in low-grade glioma (LGG, 13 patients) and 33% in high-grade glioma (HGG, 45 patients). These were primary CNS tumors, and no separate intracranial endpoint was reported. Progression-free survival (PFS) was 9.5 months in LGG and 5.5 months in HGG. Overall survival (OS) was not estimable in LGG and was 17.6 months in HGG. Any serious adverse event occurred in 3 of 13 LGG patients (23%) and in 16 of 45 HGG patients (36%). The authors classify this as direct CNS clinical evidence, with limitations of heterogeneous histologies and single-arm design.

In the VE-BASKET trial, patients with BRAF V600-mutant glioma received vemurafenib. The ORR was 25% in a subgroup of 24 patients. These were primary CNS tumors, and no separate intracranial endpoint was reported. Median PFS was 5.5 months, and OS was not reported here. Grade 3/4 maculopapular rash occurred in 3 of 24 patients (13%), and adverse-event discontinuation occurred in 1 of 24 patients. The authors classify this as direct CNS clinical evidence, with limitations of monotherapy and heterogeneous histologies.

In a randomized pediatric trial, patients with BRAF V600-mutant LGG received dabrafenib plus trametinib versus chemotherapy. The ORR was 47% versus 11%. These were primary CNS tumors, and no separate intracranial endpoint was reported. Median PFS was 20.1 months versus 7.4 months, and OS was not reported. In the targeted arm, all-cause grade ≥3 adverse events occurred in 34 of 73 patients (47%), treatment-related grade ≥3 events in 19 of 73 patients (26%), and adverse-event discontinuation in 3 of 73 patients (4%). The authors classify this as direct randomized pediatric evidence, not generalizable to adult entities.

In an early pediatric study, patients with BRAF V600-mutant LGG received trametinib or dabrafenib plus trametinib. The ORR was 15% and 25%, respectively. These were primary CNS tumors, and no separate intracranial endpoint was reported. PFS and OS were not reported. Adverse-event discontinuation occurred in 7 of 13 patients receiving trametinib (54%) and in 8 of 36 patients receiving the combination (22%). The authors classify this as direct pediatric clinical evidence from nonrandomized cohorts.

In the ROAR phase 2 basket cohort, patients with BRAF V600E anaplastic thyroid carcinoma received dabrafenib plus trametinib. The systemic ORR was 56% in 36 patients, with a median response duration of 14.4 months. No brain-metastasis subgroup or intracranial endpoint was reported. Median PFS was 6.7 months, and OS was 14.5 months. Any serious adverse event occurred in 20 of 36 patients (56%). None of the trial's fatal serious adverse events was treatment-related. The authors classify this as direct systemic ATC evidence only, not TCBM intracranial evidence.

In a single-center retrospective study, 16 patients with BRAF V600E thyroid cancer received dabrafenib plus trametinib. This included 10 PTC and 6 ATC patients, with two baseline TCBM cases. The systemic ORR was 50% in PTC and 67% in ATC. One evaluable case showed a 39.7% intracranial reduction after prior stereotactic radiotherapy (SRT). No cohort intracranial ORR was reported. PTC PFS and OS were not estimable. ATC median PFS was 2.7 months, and OS was 3.6 months. All-cause grade ≥3 adverse events occurred in 6 of 16 patients (38%), and there was one treatment-related death from interstitial pneumonitis. The authors classify this as direct but very limited TCBM observation, with prior SRT and two baseline cases confounding attribution.

The authors also describe melanoma brain-metastasis studies as indirect comparators. In the COMBI-MB trial, patients with melanoma brain metastases received dabrafenib plus trametinib. Overall response was not used as a TCBM endpoint. In cohort A (76 patients), the intracranial ORR was 58%. Median PFS was 5.6 months, and OS was 10.8 months. All-cause grade 3/4 adverse events occurred in 60 of 125 patients (48%), and adverse-event discontinuation in 12 of 125 patients (10%). The authors state that this indirect melanoma comparator cannot establish TCBM efficacy or drug penetration.

In the BREAK-MB trial, patients with melanoma brain metastases received dabrafenib. Overall response was not used as a TCBM endpoint. The BRAF V600E intracranial ORR was 39.2% without prior local therapy and 30.8% after prior local therapy. PFS and OS were not reported here. The authors classify this as an indirect melanoma comparator, and note that cohorts differed by prior local therapy.

In a small pilot study, 24 evaluable patients with symptomatic melanoma brain metastases received vemurafenib. Ten of 24 patients had partial responses involving intracranial and extracranial sites. Seven of 19 patients had more than 30% intracranial regression, and 3 of 19 had confirmed intracranial partial responses. Median PFS was 3.9 months, and OS was 5.3 months. Grade 3 adverse events occurred in 4 of 24 patients (17%). The authors classify this as indirect, small, symptomatic, previously treated melanoma cohort evidence, and note that intracranial and extracranial endpoints have different denominators.

In the republished 2023 TRICOTEL trial, patients with melanoma CNS metastases received atezolizumab plus vemurafenib plus cobimetinib. Overall response was not used as a TCBM endpoint. Independent-review intracranial ORR was 42%, and intracranial response duration was 7.4 months. PFS and OS were not used here. Treatment-related grade ≥3 adverse events occurred in 41 of 60 treated patients (68%), and there was one treatment-related death from limbic encephalitis. The authors used the valid 2023 republication, not the retracted 2022 article.

## Clinical Implications for Patients

The central message for patients is that a BRAF V600E mutation found in a primary brain tumor or in thyroid cancer that has spread to the brain does not mean that every treatment studied in melanoma or in systemic thyroid cancer will work the same way inside the brain.

The authors emphasize several practical points:

- Molecular eligibility must be confirmed within each specific tumor type, not inferred from a broad diagnostic label.
- How common a mutation is in a selected cohort is not a measure of how dependent a tumor is on that pathway. It is also not a measure of what cell-death phenotype the tumor has, or how much benefit a patient will receive.
- A high proportion of BRAF V600E in a selected PXA or classical PTC cohort does not show that the two diseases share co-alterations or a response mechanism.
- A lower frequency in ganglioglioma or pilocytic astrocytoma does not reduce the potential relevance of a confirmed mutation for an individual patient.
- Clinical response alone cannot identify which death pathway is engaged in a patient's lesion.

For TCBM specifically, the brain-metastasis cohort evidence is sparse. It does not permit reconstruction of a BRAF V600E prevalence estimate from extracranial PTC cohorts. Direct TCBM intracranial evidence is restricted to very limited, confounded observations.

The authors also caution that a radiographic response to BRAFi/MEKi should be described as clinical activity rather than proof that a particular apoptotic node was restored. This distinction matters because it affects how researchers design the next generation of studies.

## Limitations: What This Review Could Not Establish

The authors are explicit about the limits of the evidence. This was a narrative review, not a systematic review. It did not use a PRISMA workflow, protocol registration, dual independent screening, formal risk-of-bias assessment, or meta-analysis.

Several specific gaps limit what can be concluded:

- An integrated BRAF–apoptosis–ferroptosis network has not been directly established in TCBM.
- Genotype-defined ferroptosis studies in the selected primary CNS tumors remain lacking.
- FSP1/CoQ10 and DHODH are established general mechanisms, not validated dependencies in TCBM or the selected BRAF V600E primary CNS tumors.
- Direct validation of BRAF–MEK–ERK signaling to apoptosis in TCBM remains limited.
- Available TCBM cohorts do not provide a reliable BRAF-stratified frequency or uniform molecular profile.
- Melanoma brain-metastasis studies are indirect comparators and cannot establish efficacy in TCBM or primary BRAF V600E-mutant CNS tumors.
- Direct TCBM intracranial evidence is restricted to very limited, confounded observations.

The authors also note that the 27-patient TCBM cohort had heterogeneous histologies and treatments, and outcomes were not stratified by BRAF status. The median survival of 5.0 months after CNS-metastasis diagnosis should be interpreted with that heterogeneity in mind.

For the molecular landscape estimates, the authors repeatedly warn that cohort selection, referral population, assay method, anatomic site, and classification era affect the denominators. Historical classification may reassign some tumors under contemporary integrated diagnosis. These estimates should not be treated as universal prevalence estimates.

## Recommendations and Research Priorities

The authors identify disease-specific pharmacokinetic, mechanistic, and prospective clinical studies as priorities. They propose a structured experimental sequence to move the field forward.

For apoptosis research, the recommended sequence is:

1. Test pathway suppression within a genotype-defined model.
1. Measure BIM abundance.
1. Measure anti-apoptotic buffering.
1. Measure BAX/BAK activation.
1. Measure mitochondrial permeabilization.
1. Use rescue experiments to distinguish association from dependence.

For TCBM, paired extracranial and intracranial material would be required to determine whether the brain site changes the apoptotic threshold.

For ferroptosis research, the priority is to measure lipid-peroxidation sensitivity, iron handling, SLC7A11/GPX4 dependence, FSP1/CoQ10 activity, and DHODH dependence. These measurements should be made in molecularly characterized PXA, ganglioglioma, and paired thyroid primary/brain metastasis models. Such studies should test whether MAPK inhibition changes ferroptosis sensitivity in a compound- and context-dependent manner. They should include CNS exposure and toxicity constraints.

Minimum target-context studies should combine genetic and pharmacologic perturbation, verify lipid peroxidation-dependent death, and demonstrate rescue by a ferroptosis-specific intervention. In brain models, these endpoints should be interpreted alongside neuronal and glial toxicity and the unbound exposure achieved at the lesion.

The authors also emphasize that interpretation should remain intervention-specific. Sensitivity to one GPX4 inhibitor cannot predict sensitivity to system Xc– inhibition. A genotype-associated difference for erastin does not establish synergy with dabrafenib. An increased labile iron pool may create vulnerability, but it is not itself evidence that ferroptosis occurs in a treated patient.

For patients and families, the practical takeaway is that treatment decisions should be guided by molecular testing within the specific tumor type. Treatment decisions should also be guided by clinical trial evidence in that tumor type. Treatment decisions should also be guided by careful discussion with the treating team about the strength of the evidence. The authors' framework separates direct evidence from indirect and hypothesis-generating evidence, and that separation is the most useful tool for interpreting new findings as they emerge.

## Frequently Asked Questions

### I have a BRAF V600E mutation in a brain tumor. Does that mean treatments used for melanoma will work for me?

Not necessarily. A shared BRAF V600E mutation does not make diseases biologically equivalent. The review stresses that molecular eligibility must be confirmed within each specific tumor type, not inferred from a broad label. Melanoma brain-metastasis studies are indirect comparators and cannot establish efficacy in your tumor type. Discuss testing and trial evidence for your exact diagnosis with your treating team.

### What does it mean if my tumor report says BRAF V600E is common in this tumor type?

How common a mutation is in a selected cohort is not a measure of how dependent a tumor is on that pathway, what cell-death phenotype it has, or how much benefit a patient will receive. Frequency estimates also depend on histology, referral population, assay method, anatomic site, and classification era, so they should not be treated as universal prevalence estimates.

### Is there evidence that BRAF/MEK inhibitors work inside the brain for thyroid cancer that has spread there?

Direct evidence inside the brain for thyroid cancer brain metastases remains very limited and confounded. In one single-center retrospective study of 16 patients with BRAF V600E thyroid cancer, one evaluable case showed a 39.7% intracranial reduction after prior stereotactic radiotherapy, but no cohort intracranial response rate was reported. The authors classify this as direct but very limited observation.

### What did the ROAR trial find for adults with BRAF V600E glioma?

In the ROAR basket trial, adults with BRAF V600E glioma received dabrafenib plus trametinib. The objective response rate was 54% in low-grade glioma (13 patients) and 33% in high-grade glioma (45 patients). Progression-free survival was 9.5 months and 5.5 months respectively. These were primary CNS tumors, and no separate intracranial endpoint was reported.

### Why might a drug that works on thyroid cancer elsewhere in the body not work the same way in the brain?

The intact blood–brain barrier, the heterogeneous blood–tumor barrier, drug efflux transporters, and the brain microenvironment all complicate any inference from systemic treatment results. In experimental brain metastases, permeability varied among and within lesions, and drug uptake could remain lower than in peripheral tissue despite contrast enhancement on imaging. The authors treat these barriers as modifiers rather than deterministic explanations for resistance.

### If my scan shows my tumor shrank on a BRAF/MEK inhibitor, does that prove the drug fixed a specific cell-death pathway?

No. A clinical response alone cannot identify which death pathway is engaged in a patient's lesion. The authors caution that a radiographic response to BRAF/MEK inhibition should be described as clinical activity rather than proof that a particular apoptotic node was restored. This distinction matters because it affects how researchers design the next generation of studies.

### What is the survival outlook for thyroid cancer that has spread to the brain?

A 27-patient cohort supports the clinical importance of thyroid cancer brain metastases. In that cohort, median survival after diagnosis of CNS metastasis was 5.0 months. However, the histologies and treatments in that cohort were heterogeneous, and outcomes were not stratified by BRAF status, so this figure should be interpreted with that heterogeneity in mind.

### When should a patient with a BRAF V600E brain tumor or thyroid cancer that has spread to the brain seek a second opinion?

A second opinion is worth considering when a BRAF V600E mutation is found in a primary brain tumor or in thyroid cancer that has spread to the brain. Molecular eligibility must be confirmed within each specific tumor type, not inferred from a broad diagnostic label, and treatment decisions should be guided by molecular testing and clinical trial evidence in that tumor type. Direct intracranial evidence for thyroid cancer brain metastases remains very limited and confounded, so the strength of the evidence should be discussed carefully. Diagnostic Detectives Network provides independent expert second opinions.

## Source Information

**Original article title:** Programmed cell death evasion in BRAF V600E-driven primary CNS tumors and thyroid cancer brain metastases.

**Authors:** Jin T, Lv Y, Yang Q, Zhang R, Jin H.

**Author affiliations:** Department of Thyroid and Head and Neck Surgery II, Jilin Provincial Cancer Hospital, Changchun, China; Department of Thyroid and Head and Neck Surgery I, Jilin Provincial Cancer Hospital, Changchun, China; Department of Internal Medicine III, Jilin Provincial Cancer Hospital, Changchun, China

**Corresponding author:** Hui Jin (huijin_jpch@163.com)

**Journal:** Frontiers in Neurology, volume 17, article 1921351

**Article type:** Mini Review

**DOI:** 10.3389/fneur.2026.1921351

**Publication dates:** Received 27 June 2026; revised 30 July 2026; accepted 14 August 2026; published 02 September 2026

**Copyright:** © 2026 Jin, Lv, Yang, Zhang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

**Note:** This patient-friendly article is based on peer-reviewed research. It restructures one published review article for a general audience. All numbers, study findings, and conclusions come from the original article. This article does not provide medical advice. Patients should discuss their individual situation with a qualified healthcare professional.


---
Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay.
Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact
Canonical page: https://diagnosticdetectives.com/products/how-brain-tumors-and-thyroid-cancer-brain-metastases-with-the-braf-v600e-mutation-escape-cell-death